Novel biomarkers and neuroimaging techniques in Parkinson’s disease

Saw, A., Bari, S. and Robertson, Neil P. ORCID: https://orcid.org/0000-0002-5409-4909 2024. Novel biomarkers and neuroimaging techniques in Parkinson’s disease. Journal of Neurology 271 , pp. 1056-1058. 10.1007/s00415-024-12187-6

PDF - Published Version Available under License Creative Commons Attribution. Download (475kB)

Abstract

Parkinson’s disease (PD) is one of the world’s most common neurodegenerative disorders, with global prevalence now expected to increase to 14 million in 2040. Although PD remains a leading cause of neurological disability, there remain a number of hurdles to optimise long-term clinical management. In particular, PD is currently diagnosed by clinical criteria which heavily rely on the expression of classical motor symptoms which occur relatively late in the pathological process. However, earlier or pre-symptomatic diagnosis would ofer the opportunity to explore the role of neuroprotective or disease-modifying therapies. In addition, a more detailed understanding of the mechanisms of non-pharmacological interventions would allow the application of more personalised approach to interventions and a better understanding of underlying disease processes. In this month’s journal club, we review a study using cerebrospinal fuid (CSF) α-synuclein as novel diagnostic biomarker and two neuroimaging studies exploring the neural mechanisms responsible for success of aerobic exercise and optimisation of DBS parameters in PD.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/, Type: open-access
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	1 February 2024
Date of Acceptance:	3 January 2024
Last Modified:	01 Feb 2024 10:30
URI:	https://orca.cardiff.ac.uk/id/eprint/166008

Actions (repository staff only)

Edit Item